Amgen Fights FDA Bid to Withdraw Tavneos, Submits Data in Defense

Amgen has pushed back this week against a U.S. Food and Drug Administration proposal to withdraw its rare-disease treatment Tavneos (avacopan) from the U.S. market. On July 23, 2026, Amgen submitted a scientific data package to seek a hearing aimed at preserving access to the drug, delivering the response on October 3, 2026 in publicly released company statements.

In its statement, Amgen described Tavneos as a vital treatment option for patients living with severe active antineutrophil cytoplasmic autoantibody–associated vasculitis (AAV), arguing the FDA’s withdrawal proposal ignores the drug’s favorable benefit–risk profile. The company emphasized challenges in treating rare diseases like AAV, including delayed diagnoses, and highlighted its submission of extensive analyses demonstrating Tavneos meets the statutory standard for substantial evidence of effectiveness.

Amgen said it disagrees with the FDA’s proposal and looks forward to a “science‑ and patient‑focused engagement” to present the totality of evidence supporting the drug, including the seriousness of AAV and limitations of existing treatment alternatives.

Why it matters for investors

Tavneos, acquired via Amgen’s purchase of ChemoCentryx in 2022, represents a meaningful asset in the company’s rare disease portfolio. The FDA’s potential withdrawal could significantly disrupt treatment access for a vulnerable patient population and impact Amgen’s positioning in rare disease therapeutics.

With the submission of detailed evidence and the request for a hearing, Amgen is taking decisive regulatory action. Any determination by the FDA to retain or withdraw Tavneos will likely carry substantial implications for Amgen’s regulatory credibility and investor sentiment around its rare-disease pipeline.

Looking ahead

The next key step will be whether the FDA grants the requested hearing and, if so, the timing and outcome of that hearing. Investors should monitor updates from both Amgen and the FDA closely, as the decision could influence not only Tavneos’s future but also broader rare-disease strategy and pipeline risk for the company.